Loading…

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively as...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2021-12, Vol.39 (12), p.4355-4361
Main Authors: Katayama, Satoshi, Mori, Keiichiro, Pradere, Benjamin, Laukhtina, Ekaterina, Schuettfort, Victor M., Quhal, Fahad, Motlagh, Reza Sari, Mostafaei, Hadi, Grossmann, Nico C., Rajwa, Pawel, Moschini, Marco, Mathieu, Romain, Abufaraj, Mohammad, D’Andrea, David, Compérat, Eva, Haydter, Martin, Egawa, Shin, Nasu, Yasutomo, Shariat, Shahrokh F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23
cites cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23
container_end_page 4361
container_issue 12
container_start_page 4355
container_title World journal of urology
container_volume 39
creator Katayama, Satoshi
Mori, Keiichiro
Pradere, Benjamin
Laukhtina, Ekaterina
Schuettfort, Victor M.
Quhal, Fahad
Motlagh, Reza Sari
Mostafaei, Hadi
Grossmann, Nico C.
Rajwa, Pawel
Moschini, Marco
Mathieu, Romain
Abufaraj, Mohammad
D’Andrea, David
Compérat, Eva
Haydter, Martin
Egawa, Shin
Nasu, Yasutomo
Shariat, Shahrokh F.
description Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. Results Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77; P  = 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48; P  = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31; P  = 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3; P  = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. Conclusion Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.
doi_str_mv 10.1007/s00345-021-03740-3
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2543445012</sourcerecordid><originalsourceid>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EokvhD3BAkbjAwTD-ip0LUlUBRVoJDnA23mSy6yqxi51E7b_HS0qBHrjY8swz74znJeQ5gzcMQL_NAEIqCpxREFoCFQ_IhkkhqNG8fkg2oLmksjHihDzJ-RKA6RrUY3IiZMG4kRvy_UuK-xDz5NtqccOMVeyr6YBVvskTjiXqx3EOSH3oBzeObvIxVD50eF3OKsRAxzm3A5bX4rJfsNoNruswVa0LLaan5FHvhozPbu9T8u3D-6_nF3T7-eOn87MtbRWYiSpQyE1tHKubRrfIOscaw1rcdU3NEfqml6wTqtG1Ukah0VIXuOl4j9jtuDgl71bdq3k3YtdimJIb7FXyo0s3Njpv_80Ef7D7uFhTlwVqWQRerwKHe2UXZ1t7jEHZmOIACyvsq9tmKf6YMU929LnFYXAB45wtV1JIqYAd53p5D72McwplFYVqjBFKgC4UX6k2xZwT9ncTMLBHs-1qti2z2l9mW1GKXvz95buS3-4WQKxALqmwx_Sn939kfwIyoLUt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2598835307</pqid></control><display><type>article</type><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><source>Springer Nature</source><creator>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F.</creator><creatorcontrib>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F. ; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU) ; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><description>Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. Results Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77; P  = 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48; P  = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31; P  = 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3; P  = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. Conclusion Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-021-03740-3</identifier><identifier>PMID: 34143284</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Bladder cancer ; Cancer ; Decision making ; Female ; Humans ; Inflammation ; Inflammation - etiology ; Invasiveness ; Life Sciences ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Neoplasm Invasiveness ; Nephrology ; Oncology ; Original ; Original Article ; Patients ; Prediction models ; Prognosis ; Retrospective Studies ; Risk Assessment ; Urinary Bladder Neoplasms - complications ; Urinary Bladder Neoplasms - immunology ; Urinary Bladder Neoplasms - pathology ; Urology</subject><ispartof>World journal of urology, 2021-12, Vol.39 (12), p.4355-4361</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</citedby><cites>FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</cites><orcidid>0000-0002-8377-2457 ; 0000-0002-6603-6319 ; 0000-0002-8163-6953 ; 0000-0002-6147-6569 ; 0000-0002-8953-0272</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34143284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03285200$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayama, Satoshi</creatorcontrib><creatorcontrib>Mori, Keiichiro</creatorcontrib><creatorcontrib>Pradere, Benjamin</creatorcontrib><creatorcontrib>Laukhtina, Ekaterina</creatorcontrib><creatorcontrib>Schuettfort, Victor M.</creatorcontrib><creatorcontrib>Quhal, Fahad</creatorcontrib><creatorcontrib>Motlagh, Reza Sari</creatorcontrib><creatorcontrib>Mostafaei, Hadi</creatorcontrib><creatorcontrib>Grossmann, Nico C.</creatorcontrib><creatorcontrib>Rajwa, Pawel</creatorcontrib><creatorcontrib>Moschini, Marco</creatorcontrib><creatorcontrib>Mathieu, Romain</creatorcontrib><creatorcontrib>Abufaraj, Mohammad</creatorcontrib><creatorcontrib>D’Andrea, David</creatorcontrib><creatorcontrib>Compérat, Eva</creatorcontrib><creatorcontrib>Haydter, Martin</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Nasu, Yasutomo</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. Results Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77; P  = 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48; P  = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31; P  = 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3; P  = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. Conclusion Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</description><subject>Aged</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Decision making</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - etiology</subject><subject>Invasiveness</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Urinary Bladder Neoplasms - complications</subject><subject>Urinary Bladder Neoplasms - immunology</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhi0EokvhD3BAkbjAwTD-ip0LUlUBRVoJDnA23mSy6yqxi51E7b_HS0qBHrjY8swz74znJeQ5gzcMQL_NAEIqCpxREFoCFQ_IhkkhqNG8fkg2oLmksjHihDzJ-RKA6RrUY3IiZMG4kRvy_UuK-xDz5NtqccOMVeyr6YBVvskTjiXqx3EOSH3oBzeObvIxVD50eF3OKsRAxzm3A5bX4rJfsNoNruswVa0LLaan5FHvhozPbu9T8u3D-6_nF3T7-eOn87MtbRWYiSpQyE1tHKubRrfIOscaw1rcdU3NEfqml6wTqtG1Ukah0VIXuOl4j9jtuDgl71bdq3k3YtdimJIb7FXyo0s3Njpv_80Ef7D7uFhTlwVqWQRerwKHe2UXZ1t7jEHZmOIACyvsq9tmKf6YMU929LnFYXAB45wtV1JIqYAd53p5D72McwplFYVqjBFKgC4UX6k2xZwT9ncTMLBHs-1qti2z2l9mW1GKXvz95buS3-4WQKxALqmwx_Sn939kfwIyoLUt</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Katayama, Satoshi</creator><creator>Mori, Keiichiro</creator><creator>Pradere, Benjamin</creator><creator>Laukhtina, Ekaterina</creator><creator>Schuettfort, Victor M.</creator><creator>Quhal, Fahad</creator><creator>Motlagh, Reza Sari</creator><creator>Mostafaei, Hadi</creator><creator>Grossmann, Nico C.</creator><creator>Rajwa, Pawel</creator><creator>Moschini, Marco</creator><creator>Mathieu, Romain</creator><creator>Abufaraj, Mohammad</creator><creator>D’Andrea, David</creator><creator>Compérat, Eva</creator><creator>Haydter, Martin</creator><creator>Egawa, Shin</creator><creator>Nasu, Yasutomo</creator><creator>Shariat, Shahrokh F.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8377-2457</orcidid><orcidid>https://orcid.org/0000-0002-6603-6319</orcidid><orcidid>https://orcid.org/0000-0002-8163-6953</orcidid><orcidid>https://orcid.org/0000-0002-6147-6569</orcidid><orcidid>https://orcid.org/0000-0002-8953-0272</orcidid></search><sort><creationdate>20211201</creationdate><title>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</title><author>Katayama, Satoshi ; Mori, Keiichiro ; Pradere, Benjamin ; Laukhtina, Ekaterina ; Schuettfort, Victor M. ; Quhal, Fahad ; Motlagh, Reza Sari ; Mostafaei, Hadi ; Grossmann, Nico C. ; Rajwa, Pawel ; Moschini, Marco ; Mathieu, Romain ; Abufaraj, Mohammad ; D’Andrea, David ; Compérat, Eva ; Haydter, Martin ; Egawa, Shin ; Nasu, Yasutomo ; Shariat, Shahrokh F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Decision making</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - etiology</topic><topic>Invasiveness</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Urinary Bladder Neoplasms - complications</topic><topic>Urinary Bladder Neoplasms - immunology</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayama, Satoshi</creatorcontrib><creatorcontrib>Mori, Keiichiro</creatorcontrib><creatorcontrib>Pradere, Benjamin</creatorcontrib><creatorcontrib>Laukhtina, Ekaterina</creatorcontrib><creatorcontrib>Schuettfort, Victor M.</creatorcontrib><creatorcontrib>Quhal, Fahad</creatorcontrib><creatorcontrib>Motlagh, Reza Sari</creatorcontrib><creatorcontrib>Mostafaei, Hadi</creatorcontrib><creatorcontrib>Grossmann, Nico C.</creatorcontrib><creatorcontrib>Rajwa, Pawel</creatorcontrib><creatorcontrib>Moschini, Marco</creatorcontrib><creatorcontrib>Mathieu, Romain</creatorcontrib><creatorcontrib>Abufaraj, Mohammad</creatorcontrib><creatorcontrib>D’Andrea, David</creatorcontrib><creatorcontrib>Compérat, Eva</creatorcontrib><creatorcontrib>Haydter, Martin</creatorcontrib><creatorcontrib>Egawa, Shin</creatorcontrib><creatorcontrib>Nasu, Yasutomo</creatorcontrib><creatorcontrib>Shariat, Shahrokh F.</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><creatorcontrib>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayama, Satoshi</au><au>Mori, Keiichiro</au><au>Pradere, Benjamin</au><au>Laukhtina, Ekaterina</au><au>Schuettfort, Victor M.</au><au>Quhal, Fahad</au><au>Motlagh, Reza Sari</au><au>Mostafaei, Hadi</au><au>Grossmann, Nico C.</au><au>Rajwa, Pawel</au><au>Moschini, Marco</au><au>Mathieu, Romain</au><au>Abufaraj, Mohammad</au><au>D’Andrea, David</au><au>Compérat, Eva</au><au>Haydter, Martin</au><au>Egawa, Shin</au><au>Nasu, Yasutomo</au><au>Shariat, Shahrokh F.</au><aucorp>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</aucorp><aucorp>European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>39</volume><issue>12</issue><spage>4355</spage><epage>4361</epage><pages>4355-4361</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) Methods In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. Results Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23–2.77; P  = 0.003) and CSS (HR 2.53; 95% CI 1.42–4.48; P  = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57–7.31; P  = 0.002) and CSS (HR 4.93; 95% CI 1.70–14.3; P  = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. Conclusion Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34143284</pmid><doi>10.1007/s00345-021-03740-3</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-8377-2457</orcidid><orcidid>https://orcid.org/0000-0002-6603-6319</orcidid><orcidid>https://orcid.org/0000-0002-8163-6953</orcidid><orcidid>https://orcid.org/0000-0002-6147-6569</orcidid><orcidid>https://orcid.org/0000-0002-8953-0272</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0724-4983
ispartof World journal of urology, 2021-12, Vol.39 (12), p.4355-4361
issn 0724-4983
1433-8726
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8602174
source Springer Nature
subjects Aged
Bladder cancer
Cancer
Decision making
Female
Humans
Inflammation
Inflammation - etiology
Invasiveness
Life Sciences
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Invasiveness
Nephrology
Oncology
Original
Original Article
Patients
Prediction models
Prognosis
Retrospective Studies
Risk Assessment
Urinary Bladder Neoplasms - complications
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - pathology
Urology
title Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A28%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20the%20systemic%20immune-inflammation%20index%20in%20non-muscle%20invasive%20bladder%20cancer&rft.jtitle=World%20journal%20of%20urology&rft.au=Katayama,%20Satoshi&rft.aucorp=European%20Association%20of%20Urology%E2%80%93Young%20Academic%20Urologists%20Urothelial%20Carcinoma%20Working%20Group%20(EAU-YAU)&rft.date=2021-12-01&rft.volume=39&rft.issue=12&rft.spage=4355&rft.epage=4361&rft.pages=4355-4361&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-021-03740-3&rft_dat=%3Cproquest_pubme%3E2543445012%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c508t-505e2868a16997ce1da1981cebd962e0f9f41d359765585e87478a19d2feedb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2598835307&rft_id=info:pmid/34143284&rfr_iscdi=true